(Week of Aug 2–8, 2025)
August might be peak out-of-office, but Europe’s medtech builders didn’t pack it in. Cardiology AI is scaling, workflow AI is cutting admin drag, and evidence-backed devices are crossing borders.
People
Investor POV:
Marta Gaia Zanchi, Founding Partner at Nina Capital, speaking on healthtech hype vs. reality—data moats, regulatory timing, and evidence as currency shaping founder and LP conversations.
Money flows
Ultromics raised $55M for AI cardiology diagnostics — Oxford-based echocardiography AI scaling decision support for earlier detection and heart failure insights across NHS/EU care.
Listen to this interview with Ultromics Founder and CEO Ross Upton.
SNIPR Biome gets €35M injection to advance CRISPR therapies for antimicrobial resistance. In this round there are new backers such as the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D)
Tandem Health secures $50M to build an AI-native operating system for clinical workflows across Europe.
On the press
- H1 rebound: European healthtech raised €6.21B; medtech €1.89B, digital health €0.93B; 14 megarounds set the tone for H2.
- Fitness/health tech shift to AI companions — Product teams are moving from static content to AI-guided experiences; relevant for DTx and wearable engagement. Or at least this is what Zing Coach CEO Anton Marchanka thinks.
Source: Tech.eu feature
One thing to remember
In 2025 Europe, the fastest route from “cool demo” to “signed contract” is evidence-backed AI or devices that save clinician time and improve outcomes.
Founders: design for clinical workflows, not just pilots; document outcomes and time-saved like it’s your superpower; pair dilutive with non-dilutive where it speeds trials and procurement.
Investors: back teams converting regulatory readiness and real-world evidence into purchase orders—and keep an eye on AI companions where engagement meets adherence. Europe’s healthtech summer is quiet but compounding.
This content has been enhanced with GenAI tools.
